![]() ![]() On November 3, 2022, interim clinical data from patients enrolled in cohort 1 of 4DMT’s Phase 1/2 clinical trial of 4D-710 for the treatment of cystic fibrosis lung disease was presented at the North American Cystic Fibrosis Conference, which demonstrated safety and tolerability with no 4D-710-related adverse events following aerosol delivery. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today reported third quarter 2022 financial results. 09, 2022 (GLOBE NEWSWIRE) - 4D Molecular Therapeutics, Inc. Cash, cash equivalents and marketable securities sufficient to fund operations into the first half of 2025ĮMERYVILLE, Calif., Nov. We believe that this collaboration will bring synergies between the two companies' cutting-edge research, and will ultimately lead to the development of new therapeutics for patients with ophthalmic diseases at high risk of blindness.- Interim clinical trial data from 4DMT’s Phase 1/2 clinical trial of 4D-710 for the treatment of cystic fibrosis lung disease was presented at North American Cystic Fibrosis Conference on November 3, 2022 Staying at the forefront of gene therapy technology is a key part of our strategy. 4DMT retains rights to large market non-hereditary ophthalmic diseases.”Īdam Pearson, Chief Strategy Officer (CStO) at Astellas said, “At Astellas, we have a strong commitment to developing novel treatments for ophthalmic diseases, and have positioned Blindness & Regeneration as one of the Primary Focuses of our R&D strategy. “With over 70 patients dosed to-date with R100-based product candidates in wet age-related macular degeneration and rare ophthalmic diseases, this collaboration also demonstrates the modularity of the Therapeutic Vector Evolution platform resulting in efficient design and development of new intravitreal products. “This collaboration with Astellas, a leader in AAV gene therapy, continues to validate R100 for routine intravitreal low dose delivery of genetic payloads for the treatment of retinal diseases,” David Kirn, MD, Co-Founder and Chief Executive Officer of 4DMT, said in a company news release. ![]() All three 4DMT clinical-stage ophthalmic product candidates utilize the R100 vector, including 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). It has the ability to penetrate the internal limiting membrane barrier and to efficiently transduce the entire retina, resulting in robust transgene expression within retinal cells. R100 is an adeno-associated virus (AAV) vector invented by 4DMT for intravitreal delivery. In addition, 4DMT is entitled to receive mid-single digit to double-digit, sub-teen royalties on net sales of all licensed products. 4DMT will receive $20 million upfront, and potential future option fees and milestones of up to $942.5 million including potential near-term development milestones of $15 million for the initial target. Astellas will conduct all subsequent research, development, manufacturing, and commercialization activities. Under the terms of the agreement, 4DMT will provide its proprietary R100 vector technology to Astellas to deliver Astellas’ genetic payloads for the treatment of rare monogenic diseases. Astellas Enters License Agreement with 4D Molecular Therapeutics (4DMT) to Use Proprietary Intravitreal R100 Vector for Rare Ophthalmic TargetsĪstellas Pharma and 4D Molecular Therapeutics announced a license agreement under which Astellas gains rights to utilize the intravitreal retinotropic R100 vector invented by 4DMT for one genetic target implicated in rare monogenic ophthalmic disease(s), with options to add up to two additional targets implicated in rare monogenic ophthalmic diseases after paying additional option exercise fees. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |